AstraZeneca PLC (AZN)vsChemed Corp (CHE)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
CHE
Chemed Corp
$515.97
+0.31%
HEALTHCARE · Cap: $6.78B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2265% more annual revenue ($61.37B vs $2.60B). AZN leads profitability with a 17.0% profit margin vs 10.6%. AZN appears more attractively valued with a PEG of 1.28. CHE earns a higher WallStSmart Score of 63/100 (C+).
AZN
Buy60
out of 100
Grade: C+
CHE
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for CHE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Every $100 of equity generates 31 in profit
Safe zone — low bankruptcy risk
Earnings expanding 43.7% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Trading at 8.1x book value
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : CHE
The strongest argument for CHE centers on Return on Equity, Altman Z-Score, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : CHE
The primary concerns for CHE are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
AZN profiles as a mature stock while CHE is a value play — different risk/reward profiles.
CHE carries more volatility with a beta of 0.51 — expect wider price swings.
CHE is growing revenue faster at 8.8% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
CHE scores higher overall (63/100 vs 60/100). AZN offers better value entry with a 18.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Chemed Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?